Moses said to the people in his final charge "I put before you life and death, blessing and curse. Choose life...Be strong and resolute..for the Lord will not forsake you" Deut. 30 and 31. Former US National Debate Champion and Ordained Rabbi tackles issues of Public Policy, Israel, Islamic Terrorism, Antisemitism, Jewish Wisdom and the Chicago Bears
Friday, January 22, 2016
Hadassah clinical trials for new ALS treatment ‘very encouraging
Hadassah clinical trials for new ALS treatment ‘very encouraging’
‘Close to 90 percent of patients’ showed slowed progression or improvement, researchers say
Illustrative photo of cancer research at a lab at Hadassah Medical Center in Jerusalem. (Keren Freeman/Flash90)
A new treatment tested at Hadassah Medical Center in Jerusalem and developed by an American-Israeli biotech company appears to significantly slow the progression of ALS, also known as Lou Gehrig’s disease.
According to the findings of initial clinical trialspublished Tuesday in the medical journal JAMA Neurology, the treatment, which uses a stem cell infusion protocol, is safe and offers “possible clinical benefits, to be confirmed in upcoming trials.”
Hadassah: The Women’s Zionist Organization, which owns Hadassah Medical Center, said in a news releaseissued the same daythat the clinical trials began in 2011 and use an “innovative” treatment for amyotrophic lateral sclerosis in which stem cells are harvested from the patient’s bone marrow before being injected into the cerebrospinal fluid. Twenty-six ALS patients participated in the trials of a treatment developed by BrainStorm Cell Therapeutics.
The study’s principal investigator, Dr. Dimitrios Karussis of Hadassah Medical Center, described the results as “very encouraging.”
“Close to 90 percent of patients who were injected intrathecally through the spinal cord fluid were regarded as responders to the treatment either in terms of their respiratory function or their motor disability,” he said in a statement. “Almost all of the patients injected in this way showed less progression and some even improved in their respiratory functions or their motor functions.”
A Phase 2, double blind study is running currently at the Mayo Clinic, Massachusetts General Hospital and University of Massachusetts Memorial Medical Center using a treatment protocol identical to the Hadassah trial.
“While this is absolutely by no means a cure, it is the first step in a long process in that direction,” Karussis said. “I see this treatment as being potentially one of the major future tools to treat degenerative diseases of the brain and spinal cord, in general.”
Hadassah President Ellen Hershkin said in a statement that the hospital “is eager to continue its groundbreaking work to combat ALS and similar neurodegenerative or neuroinflammatory diseases, such asmultiple sclerosis and many others.”
According to the ALS Association, the disease affects 30,000 people in the United States and 450,000 worldwide